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INTERVIEW
Dr. Janie Merkel
Ryan Blum and Janice Friend
Yale University School of Medicine, New Haven, Connecticut
Dr. Janie Merkel is the director of Yale’s Chemical Genomics Screening Facility, a high-
throughput screening laboratory that is part of the Yale University Center for Genomics and
Proteomics. The Screening Facility connects Yale researchers with industry-quality robotic
machinery and a diverse group of compound libraries, which have been used successfully
to link therapeutic targets with potential therapies.
Your lab is set up like a miniature in-
dustry facility. How do you see the
relationship between an academic
center like this and industry at large?
My work in previous jobs has been
with pharmaceutical companies, and I
know they would never send an interesting
compound out of their walls. They might
send a related one that has failed. They
have to be very careful with their intellec-
tual property.
Our work here applies to an earlier
stage, a discovery stage. A lot of faculty
here have start-ups. In some cases, we are
helping them get the data to decide whether
there is a potential therapeutic. They might
be researching a disease without a treat-
ment, so demonstrating that you can iden-
tify an interesting compound can be
valuable. The Office of Cooperative Re-
search is pretty big, and they’re the tech-
nology transfer office here at Yale.
Patenting small molecules is worth more to
Yale in terms of actual dollars, so if some-
one wants to start a company or raise
money, the business side could start from
here. It’s also potentially interesting for
their research.
I got into biotech and tool companies
in2000,aroundthetimethehumangenome
was completed. There was a huge invest-
ment in companies that did genomic tools.
The pendulum is swinging back toward
molecules and leading to potential drug
treatments. But you need to have the mole-
cule—thatisworthmoreintheintellectual
property because you have something, it’s
novel, it’s useful for this specific disease,
youknowhowtofindmore.It’snotenough
to start a tool company these days.
Another positive aspect of our rela-
tionship to industry concerns student train-
ing. Yale educates grad students and
postdocs. Many people we work with may
be thinking about industry, and this gives
them some unique experience. When they
interview at a pharmaceutical company,
most people from an academic background
don’t know the language but the process is
very similar.
Does a screening center like this
have any interest in competing with
industry in drug discovery and appli-
cation?
I don’t think it has to be a head-on
competition. A lot of companies, because
of financial pressures and the high cost of
bringing a drug to market, have cut back on
discovery. Basic researchers who hadInterview with Dr. Janie Merkel 180
worked to find new drugs are brought into
other parts of a company to add another
edge. Obviously, private companies have
many more compounds and are built for a
totally different scale, but at the end of the
day they still need new compounds, new
ideas, new proteins, and new diseases. Be-
fore the orphan drug legislation, if you
wanted to work on a disease that does not
affect hundreds of thousands of people, it
was bad business, but now the government
is helping and companies are doing it suc-
cessfully.Alot of that will start in academia
and transition later.
How are the molecules for screening
libraries discovered?
Synthetic chemists make the chemicals.
Gary Strobel, father of Yale Department of
Molecular Biophysics and Biochemistry
professor Scott Strobel, has spent his career
at the University of Utah conducting natural
extractions.At my undergraduate institution
there was a professor who liked to scuba
dive, so he would look for novel chemicals
in deep-sea sponges and then try to recreate
those molecules. They tend to be very com-
plicated: Good drugs are often small, be-
cause if they’re too big we can’t get them
into cells.The way natural chemicals are put
together is special.
Scott Strobel received a grant last year
for a four-year undergraduate course, and
over spring break the class went to Peru and
collectednaturalspecimensfromtherainfor-
est. They came back and grew microorgan-
isms that live in commensural relationships
with those plants and then made extracts and
developed various assays. We were able to
take their extracts and put them into our
plates.Theyweremixtures;youcouldisolate
the different fractions and you would see ac-
tivity.You’d continue to fractionate it and do
mass spectrometry, and before long, you
couldfigureoutwhatthesecompoundswere.
That strikes me as overwhelming: the
realization that there are so many
compounds waiting to be discovered
and that we might never find the best
ones. Is there a more analytical ap-
proach to screening small mole-
cules?
We pay close attention to structure.
With most of our screens, there are relevant
substitutions only at certain types of sites
and certain substituting groups, for example,
iodine, fluorine, and bromine. Often a num-
ber of hits have very similar structures. The
more you can survey, the more likely you’ll
find something, which is the whole concept
of libraries and miniaturization.
One example we’ve worked on is
methotrexate and the protein dihydrofo-
latereductase, which is involved in thymi-
dine synthesis. Methotrexate is a drug that
looks a lot like folic acid’s metabolite.We’re
trying to bind fluorescently labeled
methotrexate to the protein and then find a
small molecule that kicks this out very fast.
We use a tumbling difference (anisotropy)
to identify active compounds, which we then
subject to optimization and further screen-
ing. We didn’t get many hits, but the ones
we did get all have a conserved structure.
Can you give me an example of a
project that has originated here, and
how far it has gone?
One of my first projects here involved a
young faculty member in pathology who
works on a protein that makes metastases
worse in cancers. Early on, I worked with
him to optimize a colorimetric assay, which
performed very well, but we only had a few
hits from our library. He collaborated with
an enzyme kinetics expert to characterize the
competitiveness of the interactions further
and patented a few things out of that.
The National Cancer Institute has a lot
of compounds and since his project was as-
sociated with cancer, this researcher re-
ceived about 2,000 compounds from the
institute; we helped with the screening. He
had a number of hits from the primary
screening showing good dose-response, and
he is now interested in seven of these. The
new assay is much more biologically rele-
vant than the previous way they were testing
it; there is potential for licensing. Even
though he studies a protein and its molecular
structure, collaborations like these enableInterview with Dr. Janie Merkel 181
him to work more broadly, and this kind of
screening is complementary to other meth-
ods.
How far away is this project from
clinical use, if everything goes right?
This researcher filed for a provisional
patent for the early screen. If you license it
to someone who wants to develop it, such as
a pharmaceutical company, it takes a while
— and a lot of money and time. It takes
years and years.
Have you had someone bring some-
thing from the bedside into the lab?
Yes, we did. It was an endocrinology
project. We screened a primary cell line de-
rived from a patient who had a very bizarre
tumor that expressed parathyroid hormone,
but in the pancreas. The patient had abnor-
mal calcium levels in the blood, standard
treatments failed, and the patient died. They
took tumor cells and made a cell line with
the PTH promoter behind fireﬂy luciferase
to understand what inﬂuenced expression in
this extraordinary case.
What is the next evolutionary step for
your field?
High-contentscreeningisahugegrowth
area. You get complex images with multiple
forms of information. This is different from
high-throughput screening — which we cur-
rently do — in which you get a single scalar
value for each well. More of these imaging
systems are available; a lot of detection
reagents have been around for a long time
(antibodies, stains for immunofluorescence,
flow cytometry, etc.).The software has been
used to quantify features in microscopy.
We’rejustdoingthisalotmore—andfaster.
Let’s say you identify a drug here and
you want to look at different cell types or
you want to do dose-response of a hundred
compounds. In a cell-based assay, you can
quickly get to hundreds of thousands of
samples, where this method is valuable. A
lot of people doADMETox (absorbtion, dis-
tribution, metabolism, and excretion) assays,
and the complex information is useful
downstream in cell-based systems.
Another development is increasing
miniaturization. Companies who were doing
384-well formats are now doing 1,536. New
liquid dispensing technologies use vibration
and sound waves. When you get that small,
new methods are needed to increase repro-
ducibility and manage the very high vari-
ability.
With miniaturization, the idea is to in-
crease survey space. Companies are always
adding to their compounds; they have huge
medicinal chemistry groups that are always
growing. Sometimes pharmaceutical com-
panies rescreen entire libraries to keep their
assays current.
Will some of your techniques be use-
ful in the clinic? What kinds of tech-
nological breakthroughs need to
happen for some of these ideas to be
applied?
I think so. On the epidemiologicallevel,
there will be patient stratification based on
response to treatments and tailored diagno-
sis. A lot of that will depend on genome se-
quence information or even tumor type
expression. Estrogen receptors on the sur-
face will lead to a different treatment regi-
men than for someone whose tumors don’t
express such receptors. I think these tech-
niques will grow in steps.
How much these types of things influ-
ence what drugs get developed and how they
get marketed and distributed is not known.
The NIH is discussing pharmacogenics with
biotech and pharmaceutical companies, in
which a drug that’s targeted to particular pa-
tient populations is sold with a diagnostic to
differentiate patients. A lot of tool compa-
nies are poising themselves in the diagnos-
tics field.
I don’t know how much high-through-
put will apply directly as far as the actual
techniques of personalized medicine. It will
be genomically based, gathering DNA and
RNA from blood. That will happen sooner.
Only later will someone study a variant of
something, a kinase that’s produced in peo-
ple with a certain type of cancer, and with
these techniques you could look for in-
hibitors.